Group B Streptococcus (GBS) is the leading cause of bacterial infection in newborns in the United States. To address the problem CDC developed prevention guidelines in collaboration with the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) and published the guidelines in the Morbidity and Mortality Weekly Report in 1996. This evaluation assessed the management of GBS disease in the United States, looking at the extent to which the guidelines were followed and factors associated with poor compliance. Results showed that implementation of the new GBS prevention guidelines was successful at the test site (Group Health Cooperative of Puget Sound) and was accomplished in a short time period. More complete compliance with GBS guidelines helped to improve clinical outcomes for mothers with GBS infections. A cost benefit analysis showed that the costs of delivering antibiotics is minimal compared with the potential health and economic benefits from reduced infant mortality. This population-based evaluation is a good example of collaboration between managed care organizations and public health agencies to determine the impact of national disease prevention guidelines on health care providers.
AGENCY SPONSOR: National Center for Infectious Diseases
FEDERAL CONTACT: Anne Schuchat, 404-639-2215
PIC ID: 6333
PERFORMER: American Association of Health Plans, Washington, DC